EDUCATION

  • Ph.D. (Statistics)1985, University of Chicago
  • M.S. (Statistics) 1975, University of Chicago
  • B.A. (Mathematics & Computer Science) 1974, University of Illinois

RESEARCH INTERESTS

  • Clinical trials and clinical trials methodology
  • Survival analysis

SELECTED PUBLICATIONS

  • Catenacci D, Cervantes G, Yala S, Nelson EA, El-Hashani E, Kanteti R, Dinali M, Hasina R, Bragelmann J, Seiwert T, Sanicola M, Henderson L, Grushko TA, Olopade O, Karrison T, Bang Y-J, Kim W Tretiakova M, Vokes E, Frank DA, Kindler H, Huet H, Salgia R (2011). RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adencarcinoma. Cancer Biology & Therapy 12:9-46.
  • Kocherginsky M, Cohen EEW, Karrison T (2009). Design of phase II cancer trials for evaluation of cytostatic/cytotoxic agents, Journal of Biopharmaceutical Statistics 19:524-529. PMCID: PMC19384693
  • Ferguson MK, Siddique J, Karrison T (2008). Modeling major lung resection outcomes using classification trees and multiple imputation techniques, European Journal Cardio-thoracic Surgery 34:1085-1089.
  • Karrison T, Maitland ML, Stadler WM, Ratain MJ (2007). Design of phase II cancer trials using a continuous endpoint of change in tumor size: Application to a study of sorafenib and erlotinib in non-small-cell lung cancer, JNCI 99:1456-1461.
  • Dignam JJ, Karrison T, and Bryant J (2006). Design and analysis of oncology clinical trials, in Oncology: An Evidence-Based Approach, Chang et al., eds, Springer, New York.
  • Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM, Vokes EE (2005). Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23:8033-8040.
  • Meier P, Karrison T, Chappell R, Xie H. The price of Kaplan-Meier, Journal American Statistical Assn 99: 890-896 (2004).
  • Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramirez J, Rudin CM, Vokes EE, and Ratain MJ. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan, J Clin Oncology 22:1382-1388 (2004).
  • Karrison T and O'Brien PC. A rank-sum-type test for paired data with multiple endpoints, Journal of Applied Statistics 31:229-238 (2004).
  • Karrison T, Huo D, and Chappell R. A group sequential, response-adaptive design for randomized clinical trials, Controlled Clinical Trials 24:506-522 (2003).
  • Ober, C.O., Karrison T, Odem, R.R., Barnes, R.B., Branch, D. W., Stephenson, M.D., Baron, B, Walker, M.A., Scott, J.R., and Schreiber, J.R. The Recurrent Miscarriage (REMIS) Study: Mononuclear cell immunisation in prevention of recurrent miscarriages: a randomised trial, Lancet 354:365-369 (1999).
  • Karrison T, Ferguson DJ, and Meier P. Dormancy of mammary carcinoma after mastectomy. Journal of the National Cancer Institute, 90 (1999).
  • Karrison T and Ober C. Recurrent miscarriage (REMIS) study: how should data from women who do not become pregnant be handled? Controlled Clinical Trials, 19:430-439 (1998).
  • Karrison T. Confidence intervals for median survival times under a piecewise exponential model with proportional hazards covariate effects. Statistics in Medicine, 15(2):171-182 (1996).
  • Karrison T Comparison of median survival times with adjustment for covariates. Statistics in Medicine, 14(23):2537-2553 (1995).
  • Karrison T Restricted mean life with adjustment for covariates. Journal of the American Statistical Association, 82(400):1169-1176 (1987).

MAJOR COURSES

  • Statistical Methods in Clinical Research

OTHER ACTIVITIES

  • Secretary, Society for Clinical Trials, 2011-present
  • Fellow, American Statistical Association, 2009
  • Fellow, Society for Clinical Trials, 2011
  • Member, VA Cooperative Studies Scientific Merit Review Board, 2005-present
  • Program Chair, Society for Clinical Trials annual meeting, 2004
  • Board of Directors, Society for Clinical Trials, 1998-2002
  • President, Association of GCRC Statistician, 1998-1999
  • Chairman, Society for Clinical Trials Student Scholarship Committee, 1992-1995
  • Associate Editor, Controlled Clinical Trials, 1999-present
  • Member, Data Monitoring Committee
VA CSP #379 Aneurysm Detection and Management Trial (ADAM), 1992-1999
NIH-sponsored African-American Study of Kidney Disease and Hypertension (AASK), 1996-2001
NIH-sponsored Decompression Intervention of Variceal Rebleeding Trial (DIVERT), 1998-2004
VA CSP #465 Glycemic Control and Complications in Diabetes Mellitus Type II (VADT) 2002-present
VA CSP #498 Open vs. Endovascular Repair of Abdominal Aortic Aneurysms (OVER), 2002-2011


OTHER COLLEAGUES

  • Jim Dignam
  • Masha Kocherginsky
  • Michael Maitland




Last Updated: November 07, 2011



Theodore Karrison, PhD
Research Associate (Assoc.Prof.) & Director Biostat Lab
(773) 702-9326

5841 S. Maryland Ave., MC 2007, R-314
Chicago, Illinois 60637
Fax: 773-702-1979